SFS
SVA

Sowell Financial Services’s Sinovac Biotech, Ltd SVA Stock Holding History

Sowell Financial Services’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11
Closed – – 3222
2021
Q1 		$0 Buy
+11
New – ﹤0.01% 3449

Other funds holding SVA

SA
SAIF Advisors Admiralty, Hong Kong $438M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $2.66B AUM 26.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $359M AUM 23.01% 1-Year Est. Return

Sowell Financial Services's SVA Position: Q2 2021 in Review

Sowell Financial Services sold out of Sinovac Biotech, Ltd (SVA) in Q2 2021, closing a stake of 11 shares.

Sowell Financial Services first reported a position in SVA in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 28 funds tracked by Wall St. Rank hold SVA as of Q2 2021.

  • Sowell Financial Services reported no remaining Sinovac Biotech, Ltd position as of Q2 2021 after selling out during the quarter.
  • Sowell Financial Services sold 11 Sinovac Biotech, Ltd shares in Q2 2021.
  • Sowell Financial Services first reported a position in Sinovac Biotech, Ltd in Q1 2021 and held it in 1 quarter.
  • Sowell Financial Services's Sinovac Biotech, Ltd position peaked at $0 in Q1 2021.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.